Literature DB >> 36198883

Neuropathology of central nervous system involvement in TTR amyloidosis.

Ricardo Taipa1,2,3, Luísa Sousa4,5,6,7, Miguel Pinto8, Inês Reis8, Aurora Rodrigues8, Pedro Oliveira5,9, Manuel Melo-Pires8, Teresa Coelho7.   

Abstract

Hereditary transthyretin amyloidosis (ATTRv) is a systemic disease caused by the accumulation of misfolded transthyretin (TTR). It usually presents with an adult-onset progressive axonal peripheral neuropathy and cardiomyopathy. In the central nervous system (CNS), variant TTR is produced by the choroid plexus and accumulates in the leptomeninges. CNS symptoms have been increasingly recognized in this population, including transient focal neurological episodes and stroke, particularly in patients with the V30M mutation and longstanding disease. The prevalence, pathophysiology, and progression of CNS involvement remain to be clarified. The present work explores if there is a recognizable sequence of CNS TTR deposition in ATTRv. We studied the topographical and severity distribution of TTR deposition in 16 patients with ATTRv, aged 27-69 years and with a mean disease duration of 10.9 years (range: 3-29). Our results suggest that CNS pathological involvement in V30M ATTRv occurs early in the disease course, probably starting in pre-symptomatic phases, and follows a distinct sequence. Leptomeninges and subarachnoid meningeal vessels are affected earlier, then followed by perforating cortical vessels and subpial deposition, and finally by deposition in the subependymal and basal ganglia vessels near the ependymal lining. Brainstem and spinal cord show early and severe involvement, with amyloid subpial deposition already seen in initial stages. Despite massive superficial amyloid deposition, no parenchymal deposition outside subpial or subependymal regions was found. Additionally, vascular lesions or superficial cortical siderosis were not frequent. Future studies with more patients from different populations and TTR mutations will be important to confirm these findings. Defining stages of TTR pathology in the CNS may be useful to better understand pathogenic mechanisms leading to symptoms and to interpret neuroimaging biomarkers.
© 2022. The Author(s).

Entities:  

Keywords:  Central nervous system; Cerebral amyloid angiopathy; Neuropathology; Stages; Transthyretin

Year:  2022        PMID: 36198883     DOI: 10.1007/s00401-022-02501-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   15.887


  31 in total

1.  Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study.

Authors:  Sophie Bartier; Diane Bodez; Mounira Kharoubi; Florence Canouï-Poitrine; Véronique Chatelin; Carole Henrion; André Coste; Thibaud Damy; Emilie Béquignon
Journal:  Amyloid       Date:  2019-07-31       Impact factor: 7.141

2.  Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.

Authors:  Teresa Coelho; Mónica Inês; Isabel Conceição; Marta Soares; Mamede de Carvalho; João Costa
Journal:  Neurology       Date:  2018-10-17       Impact factor: 9.910

Review 3.  Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

Authors:  David Adams; Haruki Koike; Michel Slama; Teresa Coelho
Journal:  Nat Rev Neurol       Date:  2019-06-17       Impact factor: 42.937

4.  Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy.

Authors:  Johannes Attems; Kurt A Jellinger; Felix Lintner
Journal:  Acta Neuropathol       Date:  2005-08-25       Impact factor: 17.088

5.  Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology.

Authors:  Johannes Attems; Magdalena Quass; Kurt A Jellinger; Felix Lintner
Journal:  J Neurol Sci       Date:  2007-02-15       Impact factor: 3.181

6.  Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy.

Authors:  Andreas Charidimou; Valentina Perosa; Matthew P Frosch; Ashley A Scherlek; Steven M Greenberg; Susanne J van Veluw
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

7.  Association between hearing loss and hereditary ATTR amyloidosis.

Authors:  Sophie Bartier; Diane Bodez; Mounira Kharoubi; Aziz Guellich; Florence Canouï-Poitrine; Véronique Chatelin; André Coste; Thibaud Damy; Emilie Béquignon
Journal:  Amyloid       Date:  2019-09-10       Impact factor: 7.141

Review 8.  Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis.

Authors:  Andreas Charidimou; Andre Peeters; Zoe Fox; Simone M Gregoire; Yves Vandermeeren; Patrice Laloux; Hans R Jäger; Jean-Claude Baron; David J Werring
Journal:  Stroke       Date:  2012-07-12       Impact factor: 7.914

9.  Association of Key Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease With Hematoma Volume and Expansion in Patients With Lobar and Deep Intracerebral Hemorrhage.

Authors:  Gregoire Boulouis; Ellis S van Etten; Andreas Charidimou; Eitan Auriel; Andrea Morotti; Marco Pasi; Kellen E Haley; H Bart Brouwers; Alison M Ayres; Anastasia Vashkevich; Michael J Jessel; Kristin M Schwab; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein; M Edip Gurol
Journal:  JAMA Neurol       Date:  2016-12-01       Impact factor: 18.302

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.